Shares of several drugmakers soared Monday after a study published over the weekend said that their next-generation cholesterol drugs could cut the risk of heart disease, which is the world’s No. 1 killer. Highly rated Regeneron (REGN) broke out, and closed Monday’s session still in buy range. Its drug development partner Sanofi (SNY) rose on the news too. So did Amgen (AMGN), whose own heart disease treatment also showed positive results. Watch
Regeneron Pharmaceuticals (REGN) reported weaker-than-expected fourth-quarter earnings Tuesday morning, but the large-cap biotech topped sales views and offered an upbeat outlook for its blockbuster Eylea eye drug, which generates well more than half of overall revenue. Reporting before the open, Regeneron logged fourth-quarter revenue of $802.3 million, up 31% from the prior year and above consensus analyst views of $781.5 million. On the
Two hot medical stocks report fourth-quarter earnings on Tuesday. Regeneron (REGN), which develops drugs to treat eye diseases and cancer, reports before the open. Its earnings growth is projected to triple. Shares have risen 35% over the last 12 months. Medical record software maker Cerner (CERN) reports after the close. Earnings growth is expected to accelerate for a third straight quarter. Its stock has gained 21% over the last 12 months.